Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

GLP-1 Receptor antagonists used in a study allay fears about thyroid cancer.

2.

In breast-conserving surgery, is micro-CT a useful tool for determining tumor margins?

3.

Risk of a Second Primary Melanoma Similar Regardless of Race/Ethnicity

4.

Imetelstat for MDS-relateret anemia er godkendt af Food and Drug Administrations panel.

5.

Opposition to the Surgical Lymph Node Sampling Rule for Lung Resection.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot